Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Catecholamines industry 3600 synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Type trends
2.1.4 Indication trends
2.1.5 Route of administration trends
2.1.6 Distribution channel trends
Chapter 3 Catecholamines Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of chronic diseases
3.2.1.2 Growing geriatric population
3.2.1.3 Technological advancement in drug delivery system
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects and adverse reactions
3.2.2.2 Stringent regulatory framework
3.3 Growth potential analysis
3.3.1 By type
3.3.2 By indication
3.3.3 By route of administration
3.3.4 By distribution channel
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Catecholamines Market, By Type, 2018 - 2032 (USD Million)
5.1 Key trends, by type
5.2 Epinephrine (adrenaline)
5.3 Norepinephrine (noradrenaline)
5.4 Dopamine
Chapter 6 Catecholamines Market, By Indication, 2018 - 2032 (USD Million)
6.1 Key trends, by indication
6.2 Anaphylaxis
6.3 Cardiac arrest
6.4 Shock
6.5 Acute asthma
6.6 Hypertension
6.7 Other indications
Chapter 7 Catecholamines Market, By Route of Administration, 2018 - 2032 (USD Million)
7.1 Key trends, by route of administration
7.2 Intravenous
7.3 Inhalation
7.4 Transdermal
7.5 Other routes of administration
Chapter 8 Catecholamines Market, By Distribution Channel, 2018 - 2032 (USD Million)
8.1 Key trends, by distribution channel
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 Online pharmacy
Chapter 9 Catecholamines Market, By Region, 2018 - 2032 (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East & Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East & Africa
Chapter 10 Company Profiles
10.1 Pfizer, Inc.
10.2 Viatris, Inc.
10.3 Novartis International AG
10.4 Amneal Pharmaceuticals
10.5 Teva Pharmaceutical Industries Ltd
10.6 Baxter International
10.7 Breckenridge Pharmaceutical, Inc.
10.8 Lexicare Pharma Pvt. Ltd
10.9 Midas Pharma GmbH
10.10 Sun Pharmaceutical Industries Ltd.
